Urothelial carcinoma demonstrates high prevalence and is characterized by significant clinical heterogeneity. As treatment options expand, therapeutic decisions become more complex, giving multidisciplinary teams (MDT) a crucial role. This review summarizes current evidence on the impact of a multidisciplinary approach on outcomes in urothelial carcinoma.
Most urothelial carcinoma data derive from bladder cancer studies, where MDT have a substantial impact on diagnostic accuracy, improved staging quality and treatment recommendations. MDT often implement treatment changes such as the addition of intravesical or systemic therapies and improve adherence to clinical guidelines. This is associated with improved patient outcomes, although data on the effect on patient survival remains limited.
The therapeutic landscape for urothelial carcinoma is rapidly evolving with the implementation of new therapeutic options, making multidisciplinary collaboration essential for personalized treatment strategy. MDT ensure optimal diagnostical pathways, establishment of comprehensive treatment strategies, and thus potential survival benefits.
Current opinion in urology. 2026 Mar 24 [Epub ahead of print]
Anne Neuenschwander, Alessandro Uleri, Elisabeth Grobet-Jeandin, Roberto Contieri, Benjamin Pradere
Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France., Department of Urology, Josep Trueta Hospital, Girona, Spain., Department of Urology, HUG - Hôpitaux Universitaires de Genève, Geneva, Switzerland., Department of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.